LuMIERE: A Phase 1/2, Multicenter, Open-label,Non-randomized Study to Investigate Safety and Tolerability,Pharmacokinetics, Dosimetry, and Preliminary Activity of177Lu-FAP-2286 in Patients with an Advanced Solid Tumor
||Clovis Oncology, Inc.
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 68Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the experimental radiotherapy, 177Lu-FAP-2286, which researchers think may kill cancer cells by delivering radiation to cancer cells that have fibroblast activation protein (FAP). Cancers include: bladder cancer, brain and spinal tumors, breast cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancers, kidney cancer, liver cancer, lung cancer, skin cancers, pancreatic cancer, prostate cancer, sarcomas, stomach cancer, testicular cancer, and thyroid cancer.
Ryan Moy, MD
|Are you at least 18 years old?
|Have you been diagnosed with advanced cancer?